Navigation Links
Americans Confused About FDA and Drug Safety
Date:9/20/2007

h.
  • Nearly half of respondents (43 percent) believed that drug company profits were the biggest factor in drug costs, 28 percent thought drug prices were more linked to marketing costs, and only 25 percent cited the cost of research.

    • All of this shows that there's a lot of misinformation or confusion about what the FDA does, Thurber believes.

    "In addition, there is a lot of mistrust in Congress about what it should or will do with respect with laws governing the FDA," he said. "There is also a lot of concern about the safety of drugs in the United States."

    Educating the public would be a good first step, Thurber added. "The FDA needs to do a better job about being transparent and open about what they do and their findings," he said.

    Cases like the 2004 withdrawal of the painkiller Vioxx (banned after being tied to heart risks) seriously undermined the FDA's credibility and made some people wary of using any prescription drugs, he said.

    "When they see an incident like Vioxx -- they get really fearful. That's why many people think government is not doing its job," Thurber said.

    The findings in the survey were based on calls to 800 adults. The survey was conducted by the Mellman Group and Public Opinion Strategies and ran from Sept. 4 to Sept. 6, 2007. The survey has a margin of error of plus or minus 3.46 percent.

    One expert believes the survey didn't go far enough, however.

    "Instead of focusing on whether safety is important, it would be much more interesting to ask the American people whether they would be willing to make real tradeoffs in the development and availability of innovative and potentially lifesaving therapies in order to improve our safety record," said Dr. A. Mark Fendrick, a professor of health management and policy at the University of Michigan.

    "This is the real question that needs to be addressed, and it does not appear that most of
    '/>"/>

    Copyright©2007 ScoutNews,LLC.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4

    Related medicine news :

    1. Poll Finds Many Americans Misinformed About Cancer
    2. Poll Finds Many Americans Misinformed About Cancer
    3. Hypertension Drug of Choice for African Americans
    4. 38 million Americans including 14 million children left to combat hunger
    5. Americans Consume Far Too Much Salt and Sodium
    6. Americans Growing Out Of Shape
    7. Rise in Stress among Americans
    8. Home Remedies More Used By Blacks And Native Americans
    9. 90 Million Americans Harbor Drug Resistant Bacteria Inside Their Nose
    10. Aspirin, Not Used By African Americans And Diabetics To Prevent Heat Problems
    11. Americans Not Interested In Choosing Sex Of Child: Survey
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/26/2008)...ents freedom of movement, better quality of life ,... An automated artificial kidney that can be worn ...at the insulin pump is to diabetes patients. , ...orks better than conventional dialysis, according ...xperimental Nephrology . , "What,s really new a...
    (Date:7/25/2008)...wswire-USNewswire/ -- Anthony Shih,M.D., M.P.H., ...e President,of Strategic Planning, after a two-yea...ation committed to improving U.S. health system pe...ram on Health Care Quality,Improvement and Efficie.../20080725/DC28791LOGO ), Board-certified in publ...
    (Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
    (Date:7/25/2008)...sumers tips and encourages them to, ,Speak Up,(TM...uly 25 /PRNewswire-USNewswire/ -- The Pennsylvania... Patient Safety Day" which,is a national effort to...ate fully in their healthcare by asking questions ...ry or illness., "We understand the important role...
    Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
    ...urprisingly few doctors are ‘logged’ in. For year... Internet technology and result in doctor- patie...ed. Research published in Wall Street Journal Onl...t of adults receive e-mail from their doctors. An...
    ...taking a break has helped a doctor here to conduct...hnique of single hole surgery. Doctor Ajay Prakas...pital in Agra at around 10 p.m. Thursday night and...ill 10 a.m. Friday morning, removing 45 gall bladd...
    ...f a woman’s reproductive years, usually occurs aro...men experience //early menopause. Early menopause ... of health problems, including osteoporosis and ca...ssue of Mayo Clinic Women’s HealthSource describes...
    ...se by nearly 22 percent between 2000 and 2004 – fr... and Numbers// from the Agency for Healthcare Rese... percent during the previous seven years. AHRQ f... every five admissions resulted from people being ...
    Other Medicine News:Health News:Doctors –you’ve Got Ma 2
    (Date:7/23/2008)... July 23 /- InCode BioPharmaceutics, ... announced preclinical test,results demonstrating ...,the treatment of the rare chronic blood disorder ...plete results will be presented at the XXII,Intern... September 28,2008., The only treatment currentl...
    (Date:7/23/2008)...d on IND-Enabling Work with Protein Therapeutics t...lement System, CAMBRIDGE, Mass., July 23 /PRNewsw...it has initiated a corporate growth plan with the,...cutive officer and the,establishment of its headqu...oodruff Emlen, M.D., a co-founder of the company w...
    (Date:7/22/2008)...acy results from a multi-center 293-patient Europe... Stock Exchange Symbol: CYT, MONTREAL, July 22 /P...c., the global leader in cryotherapy products to t...ults previously presented from three,European stud... Front(R),were published earlier today in the Jou...
    (Date:7/22/2008)...under Therapeutics Development Initiative bring MJ... next deadline January 20,2009, NEW YORK, July 2...n to,speed delivery of transformative treatments a...Fox Foundation for Parkinson,s Research has awarde...search teams. The awards,were granted under MJFF,s...
    Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 1Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 2Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 4Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 1Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 2Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 1Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 4Field Museum Launches Shared Bike Program for Employees 15487 1Field Museum Launches Shared Bike Program for Employees 15487 2
    ...SINESS WIRE)--Jun 5, 2007 - NovaDel Pharma,Inc. (A...loping,oral spray formulations for a broad range o...o clinical studies comparing zolpidem,oral spray w...cokinetic (PK), pharmacodynamic (PD) and safety ob...as Ambien(R), a leading,drug for the treatment of ...
    ... III Study Results Presented At ASCO -- , CHICAGO ...ith,pegylated interferon alfa-2b in stage III mela...apse-free survival (RFS),according to the results...atients with stage III melanoma. Results of the Ph...r the Research and,Treatment of Cancer (EORTC) and...
    Other Medicine Technology:NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 2NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 3NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 5NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 6NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 7Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5
    ...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
    ...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
    ...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
    ...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
    Medicine Products: